anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ovarian cancer (OC) remains the most fatal disease of gynaecologic malignant tumours. The neovasculature in the tumour microenvironment principally comprises endothelial cells. Haematogenous cancer metastases are significantly impacted by tumour neovascularisation, which predominantly depends on the tumour-derived endothelial vasculogenesis. There is an urgent need for biomarkers for the diagnosis, prognosis and prediction of drug response. Endothelial cells play a key role in angiogenesis and other forms of tumour vascularisation. Subtypes of circulating endothelial cells may provide interesting non-invasive biomarkers of advanced OC that might have the potential to be included in clinical analysis for patients' stratification and therapeutic management. In this review, we summarise the reported studies on circulating endothelial subtypes in OC, detailing their isolation methods as well as their potential diagnostic, prognostic, predictive and therapeutic utility for clinical application. We highlight key biomarkers for the identification of circulating endothelial cell subtypes and their targets for therapies and critically point out future challenges.
Cilengitide administered intravenously at 2000 mg twice weekly, while Bevacizumab administered intravenously at 10 mg/kg every other week. Each cycle of therapy will be 4 weeks long.
BACKGROUND AND OBJECTIVE: With European Medicines Agency approval of PARP inhibitors in metastatic castration-resistant prostate cancer and ongoing trials in metastatic hormone-sensitive prostate cancer, detection of genetic alterations in BRCA1/2 and other homologous recombination repair genes has gained an important role. Our aim was to investigate the feasibility and comparability of comprehensive next-generation sequencing (NGS) of liquid biopsy (LB; circulating tumor DNA) and tumor tissue (TT) samples in a real-world clinical setting.
METHODS: The study cohort consisted of 50 patients with metastatic prostate cancer (mPC) who had TT NGS performed for BRCA1/2 alterations and consent for additional LB NGS. The Oncomine Comprehensive Assay v3 (Thermo Fisher Scientific, Waltham, MA, USA) was used for TT NGS. The Guardant360 83-gene assay (Guardant Health, Palo Alto, CA, USA) was used for LB NGS, including all types of somatic alterations, microsatellite instability, and blood tumor mutational burden. We calculated BRCA1/2 alteration rates and the negative percentage agreement (NPA) and positive percentage agreement (PPA) between TT and LB results.
KEY FINDINGS AND LIMITATIONS: TT NGS was successful in 44/50 patients (88%), with pathogenic BRCA1/2 alterations detected in four (9%). LB NGS was successful in all 50 patients (100%), with BRCA1/2 alterations detected in ten (20%). In a subgroup analysis for the 44 patients with successful TT NGS, NPA was 85% and PPA was 50%. The median time between TT sample collection and blood sampling for NGS was 132 wk (IQR 94-186). The limited sample size and differences in the time of NGS assessment are limitations.
CONCLUSIONS AND CLINICAL IMPLICATIONS: LB NGS resulted in a higher detection rate for BRCA1/2 alterations in comparison to conventional TT NGS (20% vs 9%). Ideally, BRCA1/2 testing should be based on both approaches to identify all patients with mPC eligible for PARP inhibitor therapy.
PATIENT SUMMARY: Our study shows that genetic tests for both tumor tissue and blood samples results in higher rates of detection of BRCA1/2 gene alterations in patients with metastatic prostate cancer.
Since calcitriol is the most potent metabolite of vitamin D available, prescription-based doses of vitamin D and its derivatives should be withheld or used with caution during treatment to avoid the risk of hypercalcemia. 

A non-aluminum phosphate-binding compound should be used to control serum phosphorous levels in patients undergoing dialysis. 

Overdosage of any form of vitamin D is dangerous (see also OVERDOSAGE). Progressive hypercalcemia due to overdosage of vitamin D and its metabolites may be so severe as to require emergency attention. Chronic hypercalcemia can lead to generalized vascular calcification, nephrocalcinosis and other soft-tissue calcification. The serum calcium times phosphate (Ca x P) product should not be allowed to exceed 70 mg2/dL2. Radiographic evaluation of suspect anatomical regions may be useful in the early detection of this condition.
PURPOSE:To obtain a double membrane lipid composition which enables the absorption of dolichol through the digestive tracts and the oral administration of dolichol, by dissolving a dolichol useful as a medicine such as a hematinic agent and a phospholipid at a specific ratio in an organic solvent, and mixing the solution in the presence of a specific amount of water. CONSTITUTION:The titled composition can be produced by dissolving (A) 8-40pts.wt. of the compound of formula I (the group of formula II is trans- isoprene unit; the group of formula III is cis-isoprene unit; n is integer of 12-18) or its ester (abbreviated as dolichol) and (B) 100pts. of the compound of formula IV (R<1-2> are 15-21C hydrocarbon group; X<1> is -CH2CH2N<+>H3, etc.) and/or formula V [X<2> is -CH2CH(OH)CH2OH, etc.] (abbreviated as phospholipid) in an organic solvent, distilling off the solvent, adding 500-100,000pts.wt. of water to the residue, and stirring the mixture. The absorption through the digestive tract and the oral administration are enabled by the proper selection of the weight ratio of dolichol to the phospholipid.
The present invention relates to a method for generating batches of lymphocytes with averaged potency. In particular, the present invention relates to a method of pooling lymphocytes from different donors to avoid NK alloreactivity and anti-HLA immune response. Lymphocytes from each donor are inactivated for at least a gene encoding a TCR component, and are pooled together before be administrated to a subject in need thereof. Thus, this method allows generating batches of lymphocytes with averaged potency, particularly to treat cancer, viral infection or auto-immune disease. The present invention also relates to a batch of lymphocytes obtainable by this method. The batch of lymphocytes can be used to be administrated to one or several patients, being made available as an “off the shelf” therapeutic product, in particular to treat cancer, auto-immune disease or viral infection.
BACKGROUND: Transbronchial microwave ablation in treating lung nodules is gaining popularity. However, microwave ablation in subpleural lung nodules raised concerns about pleural-based complications due to the proximity between the pleura and the ablation zone.
METHODS: Patients who underwent transbronchial microwave ablation between March 2019 and November 2022 were included in this analysis. The lung nodules were categorized into the subpleural group-less than 5 mm distance to the nearest pleural surface; the deep nodule group-larger or equal to 5 mm distance to the nearest pleural surface. A review of the safety profile of subpleural lung nodule ablation was conducted.
RESULTS: Eighty-two lung nodules (n = 82) from 77 patients were treated. The mean nodule size was 14.2 ± 5.50 mm. The technical success rate was 100%. The mean procedural time was 133 min. No statistically significant differences were detected in the complication rate and the length of stay between the subpleural and deep nodule groups. Complications occured in 21 nodules (25.6%). No minor pneumothorax was reported. Total five cases of pneumothorax required drainage were observed (6.06% in subpleural nodules [n = 2] vs. 6.12% in deep nodules [n = 3], p = 0.991). Total seven cases of pleuritic chest pain were observed (12.1% in subpleural nodules [n = 4] vs. 6.12% in deep nodules [n = 3], p = 0.340).
CONCLUSIONS: This single-center retrospective analysis found no significant difference in the safety outcomes between subpleural and nonsubpleural lung nodule ablation. The overall rate of complications was low in the cohort. This demonstrated that transbronchial microwave was feasible and safe for most lung nodules.
The invention relates to the field of drug production, and particularly discloses an automatic device for producing tablets. The automatic device at least comprises a tablet pressing system and a packaging system. The tablet pressing system at least comprises a smashing and grinding device, a powder weighing device and a powder tablet-pressing device. The packaging system at least comprises a stamping device, a hot-pressing cutting device and a packaging material conveying device. The lozenge production device further comprises a tablet conveying device and a control system. The tablet conveying device is used for conveying tablets prepared by the tablet pressing system into the packaging system. The control system is used for controlling the tablet pressing system, the packaging system and the tablet conveying device to cooperatively work. According to the lozenge production device, the whole process is automatically carried out, and one device can be managed only through one worker; compared with a traditional lozenge production technology, the space occupied by the device is small, processing efficiency is high, human cost and management cost are greatly reduced, and economic benefits are obviously increased.
Dehydration has been observed and may cause acute renal failure which can be fatal. Patients with pre-existing compromised renal function or who are receiving concomitant Capecitabine with known nephrotoxic agents are at higher risk. Patients with anorexia, asthenia, nausea, vomiting or diarrhea may rapidly become dehydrated. Monitor patients when Capecitabine is administered to prevent and correct dehydration at the onset. If grade 2 (or higher) dehydration occurs, Capecitabine treatment should be immediately interrupted and the dehydration corrected. Treatment should not be restarted until the patient is rehydrated and any precipitating causes have been corrected or controlled. Dose modifications should be applied for the precipitating adverse event as necessary [see Dosage and Administration (2.3)]. 

Patients with moderate renal impairment at baseline require dose reduction [see Dosage and Administration (2.4)]. Patients with mild and moderate renal impairment at baseline should be carefully monitored for adverse reactions. Prompt interruption of therapy with subsequent dose adjustments is recommended if a patient develops a grade 2 to 4 adverse event as outlined in Table 2 [see Dosage and Administration (2.3), Use in Specific Populations (8.7), and Clinical Pharmacology (12.3)].
AIMS: Attention-deficit with hyperactivity disorder (ADHD) is associated with obesity and impacts the outcome of metabolic and bariatric surgery (MBS). This study aimed at calculating the prevalence in candidates for MBS, which is yet unclear.
METHODS: We conducted a systematic review and meta-analysis, searching three databases from their respective inception to December 2022 for studies reporting the prevalence of ADHD in adolescents and adults assessed before undergoing MBS. The protocol was registered in PROSPERO (CRD42022384914). We adhered to Meta-analysis of Observational Studies in Epidemiology (MOOSE) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines; the quality of studies was assessed with the JBI Critical Appraisal checklist. Random-effect meta-analyses were performed; confidence intervals were computed with a binomial exact method, and the pooled estimate was calculated after double arcsine transformation.
FINDINGS: Fourteen studies (24,455 adults) and three studies (299 adolescents) were selected. The quality of studies was moderate to poor; meta-analyses were performed on subgroups according to the case definition used. The prevalence is 8.94% and 9.90% in adults, and 28.73% in adolescents.
CONCLUSIONS: ADHD is three times more frequent in adults and six times more frequent in adolescents than in the general population. Recommendations are provided to improve the quality of future studies and obtain more reliable estimates of prevalence.
Relapse rates in the first few months following substance abuse treatment are as high as 50%, in spite of the immediate effectiveness of treatments such as Cognitive Behavioral Therapy (CBT). Continuing use of therapy skills following treatment is associated with maintenance of treatment gains. We have programmed a telephone to deliver pre-recorded summaries and rehearsal sessions of skills learned in therapy. The system also includes monthly feedback messages from therapists. We expect that this ad-lib access to therapy skills would allow patients to generalize skills to their personal post-treatment lives. It would also allow individuals in remote or rural areas to obtain access to assistance without travel barriers.

Comparison(s): patients completing group CBT for substance abuse will be randomly assigned to two conditions. In one condition, patients will have unlimited access to the therapeutic telephone system for 4 months. The other condition is standard care (i.e., no formal relapse prevention).
The purpose of this study is to investigate the neurological and biochemical consequences of the m.3243 A\>G mutation. Mitochondria are the powerhouses of the cell and are controlled by nuclear genetic material (DNA) and mitochondrial (mt) DNA. Mitochondrial DNA mutations impair mitochondrial function, and cause cellular energy failure. These mutations, when present in high abundance, cause neurological signs and symptoms that are clinically obvious. The investigators hypothesize that these mutations, when present in lesser abundance, will cause measurable alterations in the patient's neuropsychological profile and cerebral energy profile. This study does not involve any experimental or approved therapy. The investigators will evaluate the patient's condition with blood/urine tests, neurological exam, MRI/MRS, questionnaires, motor skills functioning, serum and urine biomarkers, and genetic testing.
PURPOSE: To obtain a composition containing an indirectly acting-type sympathetic nerve stimulator and tyrosine, having appetite-suppressive effect, and useful for body weight control. CONSTITUTION: This composition, which contains an indirectly acting-type sympathetic nerve stimulator having appetite-suppressive function (e.g. ephedrine, amphetamine, phenylpropanolamine) and tyrosine or its precursor (e.g. phenylalanine, tyrosine-contg. peptide) in the weight ratio of (1.5:1) to (5,000:1), is obtained by preparation by conventional means. This composition is pref. administered parenterally such as through intravenous injection or nasal cavity, the daily doses of the former ingredient and the latter ingredient are 3-150mg and 250mg to 15g, respectively. Without the need of increasing the dose of the former ingredient, appetite-suppressive effect can be raised, and the same appetite-suppressive effect can be afforded with a lower dose of this composition.
Aspirin is associated with serious gastrointestinal (GI) adverse reactions, including inflammation, bleeding ulceration and perforation of the upper and lower GI tract. Other adverse reactions with aspirin include stomach pain, heartburn, nausea, and vomiting.

Serious GI adverse reactions reported in the clinical trials of ASPIRIN AND OMEPRAZOLE DELAYED-RELEASE TABLETSA were: gastric ulcer hemorrhage in one of the 521 patients treated with ASPIRIN AND OMEPRAZOLE DELAYED-RELEASE TABLETSA and duodenal ulcer hemorrhage in one of the 524 patients treated with enteric-coated aspirin. In addition, there were two cases of intestinal hemorrhage, one in each treatment group, and one patient treated with ASPIRIN AND OMEPRAZOLE DELAYED-RELEASE TABLETSA experienced obstruction of the small bowel.

Although minor upper GI symptoms, such as dyspepsia, are common and can occur anytime during therapy, monitor patients for signs of ulceration and bleeding, even in the absence of previous GI symptoms. Inform patients about the signs and symptoms of GI adverse reactions.

If active and clinically significant bleeding from any source occurs in patients receiving ASPIRIN AND OMEPRAZOLE DELAYED-RELEASE TABLETSA, discontinue treatment.
NEW MATERIAL:A compound shown by the formula I (R<1> is 1-25C alkyl; R<2> is 1-6C alkyl; R<3>-R<5> are 1-6C alkyl, H, or aralkyl; A is 1-6C alkylene). EXAMPLE:A compound shown by the formula VI. USE:An anti-inflammatory agent, analgesic, or germicide. Having low stimulating action on the stomach and low toxicity. PREPARATION:A glycerin dialkyl ether shown by the formula II is reacted with phosphorus oxychloride in the presence of a base to give a compound shown by the formula III. Then, this compound shown by the formula III is reacted with an amine shown by the formula IV to give a compound shown by the formula V. Then, the compound shown by the formula V is subjected to ring opening with an acid, to give a compound shown by the formula Ia wherein R<4> of the formula I is H, and R<2> is H.
Approximately 10% of the population suffer from a cough lasting longer than 8 weeks. Compared to acute cough, which usually occurs in the context of banal respiratory tract infections, the differential diagnoses of chronic cough require an increased use of diagnostic tests and thus a structured, evidence-based approach according to current international guidelines. A targeted history (smoking status, medication, previous diseases) and ENT status are always followed by chest x‑ray and pulmonary function tests before extended diagnostics. In the case of angiotensin-converting enzyme (ACE) inhibitor use and unremarkable physical examination, a drug discontinuation test can be carried out first. In case of inconspicuous findings, a disease entity that can be treated empirically such as upper airway cough syndrome is most likely. If the cough remains unexplained, cough suppression techniques, physiotherapy or speech therapy should be sought before off-label-use of medication.
PROBLEM TO BE SOLVED: To obtain the subject antimicrobial and infection protective against Helicobacter pyroli by blending a fruit polyphenol-containing fruit juice obtained from fruits belonging to the family Rosaceae or a fruit polyphenol isolated from the fruit juice as an active ingredient. SOLUTION: The objective antimicrobial and infection protective against Helicobacter pylori bacteria are obtained by using a fruit polyphenol-containing fruit juice obtained from fruits belonging to the family Rosaceae or a fruit polyphenol (e.g. apple polyphenol or the like) isolated from the fruit juice as an active ingredient, blending a preservative, e.g. sodium benzoate, methyl p-hydroxybenzoate, sodium dehydroacetate or the like, a solution adjuvant, e.g. sodium salicylate, sodium acetate, sodium benzoate or the like, and further, when necessary, a colorant, a perfume, a flavor, a sweetener or the like and in addition, when necessary adding a diluent, e.g. water or ethanol, to pharmaceutically manufacture.
Dynamin-related protein 1 (DRP1) plays crucial roles in mitochondrial and peroxisome fission. However, the mechanisms underlying the functional regulation of DRP1 in adipose tissue during obesity remain unclear. To elucidate the metabolic and pathological significance of diminished DRP1 in obese adipose tissue, we utilized adipose tissue-specific DRP1 KO mice challenged with a high-fat diet. We observed significant metabolic dysregulations in the KO mice. Mechanistically, DRP1 exerts multifaceted functions in mitochondrial dynamics and endoplasmic reticulum (ER)-lipid droplet crosstalk in normal mice. Loss of function of DRP1 resulted in abnormally giant mitochondrial shapes, distorted mitochondrial membrane structure, and disrupted cristae architecture. Meanwhile, DRP1 deficiency induced the retention of nascent lipid droplets in ER, leading to perturbed overall lipid dynamics in the KO mice. Collectively, dysregulation of the dynamics of mitochondria, ER, and lipid droplets contributes to whole-body metabolic disorders, as evidenced by perturbations in energy metabolites. Our findings demonstrate that DRP1 plays diverse and critical roles in regulating energy metabolism within adipose tissue during the progression of obesity.
The invention relates to the field of chemical engineering, in particular to a compound and a preparation method thereof. The compound has high alpha-glucosaccharase inhibitory activity and can be used for preparing blood glucose reduction drugs. According to the preparation method, a double-chalcone type alpha-glucosaccharase inhibitor can be obtained through two-step reaction, and accordingly, reaction steps are simple. In-vitro pharmacological experiments show that the compound has a certain inhibition effect on alpha-glucosaccharase. Cellular level detection shows that the compound does not obviously affect ingestion activities of HepG-2 cells from exogenous glucose; a compound ccy-13 (1 micrometer) can obviously (p<0.05) reduce the glucose content (about 40%) of the cells, close to a positive control group PG (5 micrometers), thereby having high alpha-glucosaccharase inhibitory activity. The compound can be used for preparing the blood glucose reduction drugs.
Treatment will be given in 4 phases or steps: Induction, Transplant 1 and 2, Consolidation, and maintenance. Induction is designed to induce (or bring about) myeloma into remission. Each patient enrolled on this study will be randomly assigned to receive the above treatment alone or in combination with a drug called thalidomide. Some patients may be eligible to receive the transplant as an outpatient, based on general health and other factors.After recovery from the transplant phase of the study (approximately 6 weeks), patients originally assigned to thalidomide will resume taking it and will continue taking it throughout the rest of the study treatment. All patients will receive post-transplant consolidation treatment, which in earlier studies has been found to be helpful in maintaining patients response after transplant. Therefore, all patients will receive a combination of drugs called "D PACE" which consists of Dexamethasone, Cis-Platinum, Adriamycin, Cyclophosphamide, and Etoposide. If you are also taking thalidomide, you will continue taking it throughout, and the treatment is called "DT PACE" to include the thalidomide. No sooner than 4 weeks, and no later than 12 weeks after consolidation and if your myeloma remains in remission after consolidation therapy is complete, you will begin the last phase of the study, which is maintenance. Maintenance is designed to keep your myeloma in remission long-term.